This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Travere Therapeutics Stock (NASDAQ:RTRX) 30 days 90 days 365 days Advanced Chart Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$20.15▼$21.7150-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume2.33 million shsAverage Volume412,277 shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Read More… Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RTRX Stock News HeadlinesTravere Therapeutics anticipates FILSPARI approval for FSGS by September 2025May 2 at 2:43 AM | msn.comTravere Therapeutics price target lowered to $30 from $32 at ScotiabankApril 11, 2025 | markets.businessinsider.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 3, 2025 | American Hartford Gold (Ad)Travere Therapeutics price target raised to $47 from $45 at CanaccordApril 11, 2025 | markets.businessinsider.comTravere Therapeutics price target lowered to $27 from $31 at BofAApril 4, 2025 | markets.businessinsider.comNovartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug ApprovalApril 3, 2025 | msn.comTravere Therapeutics price target raised to $31 from $29 at BofAApril 2, 2025 | markets.businessinsider.comTravere Therapeutics price target raised to $44 from $42 at JPMorganFebruary 26, 2025 | markets.businessinsider.comSee More Headlines RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT). Company Calendar Last Earnings11/05/2020Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTRX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,430,000.00 Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales6.16 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book4.11Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$1.08 billion OptionableNot Optionable Beta0.67 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:RTRX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.